NeoGenomics, Inc. — Q1 2014 Form 10-Q
Business context and reporting period. NeoGenomics operates high-complexity clinical laboratories focused on cancer-related genetic and molecular diagnostic testing. This unaudited report covers the three months ended March 31, 2014; comparisons are with Q1 2013 unless otherwise noted. Financial statement amounts below are in millions of dollars, except per-share data and operating metrics.
Financial and operating performance
| Metric | Q1 2014 | Q1 2013 / prior date | Change |
|---|---|---|---|
| Net revenue | $18.182 | $15.657 | +16.1% |
| Gross profit / gross margin | $8.709 / 47.9% | $7.246 / 46.3% | Profit +20.2%; margin +1.6 percentage points |
| Operating income | $0.394 | $0.305 | +29.2% |
| Net income | $0.102 | $0.003 | Improved; basic and diluted EPS reported as $0.00 |
| Adjusted EBITDA, non-GAAP | $1.685 | $1.794 | Down $0.109 |
| Operating cash flow | $1.025 | $(1.330) | Improved by $2.355 |
| Cash and cash equivalents | $5.385 at March 31 | $4.834 at December 31, 2013 | Up $0.551 |
| Working capital | $12.920 at March 31 | $10.794 at March 31, 2013 | Up $2.126 |
- Requisitions increased 19.9% to 24,704 and tests performed rose 20.7% to 38,734. Average revenue per test fell 3.8% to $469 and per requisition fell 3.1% to $736.
- Cost of revenue rose 12.6% to $9.473 million, slower than revenue growth. Cost per test declined 6.5% to $245, which management attributed to improved laboratory productivity, capacity planning and process improvements.
- Operating expenses increased 19.8% to $8.315 million. General and administrative expense rose 21.1% to $5.054 million; sales and marketing rose 36.4% to $2.633 million; research and development fell 24.8% to $0.628 million, mainly due to lower stock-based compensation.
- Accounts receivable, net, was $19.262 million at March 31, versus $18.653 million at year-end. The allowance for doubtful accounts was $4.569 million, or 19.2% of gross receivables. Gross receivables over 120 days were 38% of gross receivables reported in the aging table.
- Debt and leases: the balance sheet reported $4.864 million drawn on the revolving credit line and $7.000 million in equipment capital leases, current and long-term combined. The company reported approximately $4.2 million of available credit and said it had over $9.6 million in cash and borrowing capacity. It was in compliance with credit-facility covenants at quarter-end.
- Investing cash outflow was $0.883 million; financing cash inflow was $0.409 million. Equipment leased under capital leases totaled $1.693 million in non-cash investing and financing activity.
Material changes, outlook and risks
- Revenue growth was driven by higher test volume and new clients, despite lower average revenue per test. Gross service revenue was nearly flat year over year, while contractual adjustments and discounts declined, contributing to higher reported net revenue.
- Management recorded a conservative $0.7 million reduction in revenue related to unresolved Medicare National Correct Coding Initiative edits affecting billing for certain FISH tests. The company and the American Clinical Laboratory Association sought Medicare clarification; favorable guidance could allow recognition of the amount in a future period. Timing and outcome are uncertain.
- Florida Cancer Specialists (FCS) represented 14.8% of Q1 revenue, compared with 14.3% a year earlier. The company said FCS was expected to continue internalizing some tests. An April 22, 2014 amended agreement extends the relationship through December 31, 2015 and gives NeoGenomics first-offer rights, subject to exceptions, on specified cancer testing services for FCS locations.
- Management reported launching 23 molecular tests and cancer profiles in Q1 and bringing next-generation sequencing into clinical use. It planned a limited launch of its NeoSCORE prostate test in Q2 2014 and a broader launch later in the year, subject to further validation. The company also described a Covance clinical-trials laboratory alliance and expansion of its Fort Myers facility.
- Management expected 2014 sales and marketing expense to increase modestly with test volumes while remaining stable as a percentage of revenue. It expected general and administrative costs to rise with staffing, billing activity and infrastructure needs, but to decline as a percentage of revenue as volumes grow. No specific revenue or earnings guidance was provided.
- The company anticipated approximately $6.0–$7.5 million of capital expenditures over the next year, to be funded through capital leases, cash and bank facilities. Management said resources were adequate for operating commitments, but funding availability remains relevant to planned investment.
- Key risks include reimbursement pressure and payer denials, regulatory and Medicare billing uncertainty, bad-debt and collections exposure, customer internalization and concentration, competition, capacity and staffing needs, and dependence on successful new-test development and commercialization. Testing volumes may also be seasonal and affected by holidays or severe weather.
- The filing reported no material legal proceedings, no material changes in internal control over financial reporting, and effective disclosure controls at a reasonable-assurance level.
Important facts for investors to verify
- Whether Medicare issues guidance on the FISH billing edits, and whether any portion of the $0.7 million revenue reduction is later recognized.
- Receivables aging, payer denials and bad-debt trends, especially the reported 38% of gross receivables over 120 days.
- FCS test internalization, revenue concentration and the extent to which the amended agreement translates into testing volume.
- Progress and commercial uptake of new molecular tests, next-generation sequencing and NeoSCORE, including validation and launch milestones.
- Ability to finance planned capital spending while managing revolving-credit and capital-lease obligations; the credit facility was scheduled to mature March 26, 2015.
- Whether volume growth and laboratory efficiency sustain margin improvement while average revenue per test remains under pressure.